The Christie is one of Europe's leading cancer centres, treating over 60,000 patients a year. We have a history of over 100 years of leading cancer care.
Based in Manchester, we provide a networked service to a population of 3.2 million across Greater Manchester and Cheshire, delivering care as close to patients’ homes as possible. As a national specialist centre, around a quarter of our patients come to us from across the UK.
The Christie Pathology Partnership (CPP) is a joint venture between SYNLAB and The Christie NHS Foundation Trust in Manchester. SYNLAB in the UK is a trusted expert in clinical laboratory services. Commencing in 2014, the Partnership will run for 10 years and operates out of the existing Christie pathology laboratories, where around 70 staff have transferred from the NHS to the CPP.
At The Christie, we welcome any feedback – good or bad – about any aspect of your contact with the hospital. You can find out how to give us your feedback here.
Photodynamic therapy (PDT) is a non-surgical treatment which uses a light-sensitive drug (photosensitizer) to destroy cancer cells. It can be used to treat different types of cancer, including a type of skin cancer called basal cell carcinoma (BCC).
The Christie Prostate Easy Access Support Service (PEASS) is a self-management follow up pathway for patients after prostate cancer treatment or only on hormone therapy treatment.
The Christie is home to the UK's first high energy proton beam therapy service, an advanced form of radiotherapy that can be used to treat some cancers.
The service provides psychiatric assessment and treatment, psychotherapy, cognitive behavioural therapy and counselling to adult patients at The Christie with acute or chronic psychological problems.
The Christie Pharmacy Company provides a number of services for patients. Our aim is to provide a service focused around the patient and to dispense medication in a professional and efficient way.
© 2024 The Christie NHS Foundation Trust
The Christie Charity